SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
General issues related to Buy American/American First; issues related to international drug pricing.
Foreign entity interest: Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH New | — |
| FRANCIS JOGUES RIENZO | — |
Torts TOR
General issues related to patent reform; H.R. 2376 Drug Diversion and Counterfeit Crackdown Act of 2017 to increase penalties for drug diversion.
Foreign entity interest: Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT New | House Energy and Commerce Committee Counsel |
| MARYANNE DOLBEARE DUNLAP | — |
| SARA FROELICH New | — |
Taxation/Internal Revenue Code TAX
General issues related to border adjustability tax; issues related to interest deductibility; issues related to Orphan Drug Tax Credit.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH New | — |
| AMY L REDL | — |
Economics/Economic Development ECN
Issues related to Foreign Direct investment; and issues related to site expansions.
Foreign entity interest: Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY L REDL | — |
Copyright/Patent/Trademark CPT
General issues related to international intellectual property.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH New | — |
Health Issues HCR
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT New | House Energy and Commerce Committee Counsel |
| MARYANNE DOLBEARE DUNLAP | — |
| SARA FROELICH New | — |
| ADAM GLUCK New | — |
| JACOB ANDREW HARTSFIELD | — |
| AMY L REDL | — |
| FRANCIS JOGUES RIENZO | — |
Medicare/Medicaid MMM
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT New | House Energy and Commerce Committee Counsel |
| MARYANNE DOLBEARE DUNLAP | — |
| SARA FROELICH New | — |
| AMY L REDL | — |
| FRANCIS JOGUES RIENZO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.